Durvalumab and Tremelimumab for Pediatric Malignancies

Phase 1/2 Active not recruiting 50 enrolled AstraZeneca

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to determine the recommended dose of durvalumab and tremelimumab (immunotherapy drugs) in pediatric patients with advanced solid and hematological cancers and expand in a second phase to test the efficacy of these drugs once this dose is determined.

Timeline

Start: 2019-03-07
Primary completion: 2023-02-28
Completion: 2026-12-31

Publications

Hargrave D, Marshall LV, Andre N, Krystal J, Ladle BH, Robbins KA, Hois S, Armstrong J, Donegan S. Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors. Front Oncol. 2026 May 15;16:1680081. doi: 10.3389/fonc.2026.1680081. eCollection 2026.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Durvalumab	Monoclonal antibody	20 mg/kg	Intravenous
Subject	Durvalumab	Monoclonal antibody	30 mg/kg	Intravenous
Subject	Tremelimumab	Monoclonal antibody	1 mg/kg	Intravenous

Durvalumab and Tremelimumab for Pediatric Malignancies

Summary

Timeline

Publications

Drugs

Indications